Palliative effect of lafutidine on oral burning sensation

Journal of Oral Pathology and Medicine

Volumn 38, Issue 3, 2009, Pages 262-268

  Toida, M ^a   Kato, K ^a   Makita, H ^a   Long, N K ^a   Takeda, T ^a   Hatakeyama, D ^a   Yamashita, T ^a   Shibata, T ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

Burning mouth syndrome; Burning sensation; Capsaicin sensitive afferent neuron; Histamine H2 receptor antagonist; Lafutidine

Indexed keywords

AZULENE DERIVATIVE; AZULENE SULFONATE; AZUNOL; CIMETIDINE; FAMOTIDINE; LAFUTIDINE; NIZATIDINE; RANITIDINE; ROXATIDINE ACETATE; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADULT; AGED; ARTICLE; BURNING MOUTH SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GARGLE; HUMAN; MALE; NAUSEA; PAIN ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ACETAMIDES; AGED; BURNING MOUTH SYNDROME; CAPSAICIN; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; NEURONS, AFFERENT; PAIN MEASUREMENT; PALLIATIVE CARE; PIPERIDINES; PYRIDINES; SENSORY SYSTEM AGENTS; TREATMENT OUTCOME;

EID: 61349091253     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2008.00736.x     Document Type: Article

References (49)

1. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002 65 : 615 20.
2. Patton LL, Siegel MA, Benoliel R, De Laat A. Management of burning mouth syndrome: systemic review and management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007 103 : S39 44.
3. Bergdahl M, Bergdahl J. Burning mouth syndrome: prevalence and associated factors. J Oral Pathol Med 1999 28 : 350 4.
4. Miyamoto SA, Ziccardi VB. Burning mouth syndrome. Mt Sinai Med 1998 65 : 343 7.
5. Woda A, Pionchon P. A unified concept of idiopathic orofacial pain: clinical features. J Orofac Pain 1999 13 : 172 84.
6. Olesen J, Steiner TJ. The international classification of headache disorders, 2nd ed (ICHD-II). J Neurol Neurosurg Psychiatry 2004 75 : 808 11.
7. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol 2003 14 : 275 91.
8. Pinto A, Sollecito TP, DeRossi SS. Burning mouth syndrome. A retrospective analysis of clinical characteristics and treatment outcomes. NY State Dent J 2003 69 : 18 24.
9. Brailo V, Vueiaeeviae-Boras V, Alajbeg IZ, Alajbeg I, Lukenda J, Aeurkoviae M. Oral burning symptoms and burning mouth syndrome: significance of different variables in 150 patients. Med Oral Pathol Oral Cir Bucal 2006 11 : 252 5.
10. Sardella A, Lodi G, Demarosi F, Uglietti D, Carrassi A. Causative or precipitating aspects of burning mouth syndrome: a case-control study. J Oral Pathol Med 2006 35 : 466 71.
11. Forabosco A, Criscuolo M, Coukos G, et al. Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort. Oral Surg Oral Med Oral Pathol 1992 73 : 570 4.
12. Tarkkila L, Linna M, Tiitinen A, Lindqvist C, Meurman JH. Oral symptoms at menopause - the role of hormone replacement therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001 92 : 276 80.
13. Danhauer SC, Miller CS, Rhodus NL, Carlson CR. Impact of criteria-based diagnosis of burning mouth syndrome on treatment outcome. J Orofac Pain 2002 16 : 305 11.
14. Epstein JB, Marcoe JH. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. Oral Surg Oral Med Oral Pathol 1994 77 : 135 40.
15. Sardella A, Uglietti D, Demarosi F, Lodi G, Bez C, Carrassi A. Benzydamine hydrochloride oral rinses in management of burning mouth syndrome. A clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 88 : 683 6.
16. Femiano F. Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies. Minerva Stomatol 2002 51 : 405 9.
17. Gremeau-Richard C, Woda A, Navez ML, Attal N, Bouhassira D, Gagnieu MC. Topical clonazepam in stomatodynia: a randomized placebo-controlled study. Pain 2004 108 : 51 7.
18. Tammiala-Salonen T, Forssell H. Trazodone in burning mouth pain: a placebo-controlled, double-blind study. J Orofac Pain 1999 13 : 83 8.
19. Femiano F, Gombos F, Scully C, Busciolano M, De Luca P. Burning mouth syndrome (BMS): controlled open trial of the efficacy of alpha-lipoic acid (thioctic acid) on symptomatology. Oral Dis 2000 6 : 274 7.
20. Femiano F, Scully C. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med 2002 31 : 267 9.
21. Femiano F, Gombos F, Scully C. Burning mouth syndrome: open trial of psychotherapy alone, medication with alpha-lipoic acid (thioctic acid), and combination therapy. Med Oral 2004 9 : 8 13.
22. Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002 63 : 38 43.
23. Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Serpico R. Systemic capsaicin for burning mouth syndrome: short-term results of a pilot study. J Oral Pathol Med 2004 33 : 111 4.
24. Demarosi F, Tarozzi M, Lodi G, Canegallo L, Rimondini L, Sardella A. The effect of levosulpiride in burning mouth syndrome. Minerva Stomatol 2007 56 : 21 6.
25. Bergdahl J, Anneroth G, Perris H. Cognitive therapy in the treatment of patients with resistant burning mouth syndrome: a controlled study. J Oral Pathol Med 1995 24 : 213 5.
26. Tachibana T, Suzuki M, Takamori M, Ino T, Aoki M, Chiba H. Comparative study of effect by lafutidine and clotiazepam on patients with glossodynia. J Jpn Stomatol Soc 2003 52 : 188 94.
27. Tachibana T, Chiba H. Relationship between glossodynia and capsaicin sensitive sensory neurons: examination of circulatory dynamics and immunohistochemistry. J Jpn Stomatol Soc 2006 55 : 167 78.
28. 2) receptor antagonist with gastroprotective activity. I. Synthesis and pharmacological evaluation of N-phenoxypropylacetamide derivatives with thioether function. Chem Pharm Bull (Tokyo) 1998 46 : 610 5.
29. 2) receptor antagonist with gastroprotective activity. II. Synthesis and pharmacological evaluation of 2-furfuryl-thio and 2-furfurylsulfinyl acetamide derivatives with heteroaromatic rings. Chem Pharm Bull (Tokyo) 1998 46 : 616 22.
30. 2-receptor antagonistic activity. Arzneimittelforschung 1999 49 : 519 26.
31. Nishihara K, Nozawa Y, Nakano M, Ajioka H, Matsuura N. Sensitizing effects of lafutidine on CGRP-containing afferent nerves in the rat stomach. Br J Pharmacol 2002 135 : 1487 94.
32. Ichikawa T, Ishihara K, Saiagenji K, Hotta K. Effects of acid-inhibitory antiulcer drugs on mucin biosynthesis in the rat stomach. Eur J Pharmacol 1994 251 : 107 11.
33. 2-receptor antagonist, on the recurrence of gastric ulcer after healing by drug treatment in rats. Pharmacology 2000 61 : 83 90.
34. 2 antagonist: mucosal protection throughout GI tract mediated by capsaicin-sensitive afferent neurons: lafutidine protects oral to colon mucosa. Res Adv Pharmacol 2007 1 : 1 6.
35. 2 receptor antagonist, lafutidine, on neuropathic pain in rats. J Osaka Dent Univ 2005 39 : 21 5.
36. Granot M, Nagler RM. Association between regional idiopathic neuropathy and salivary involvement as the possible mechanism for oral sensory complaints. J Pain 2005 6 : 5812 7.
37. Lauria G, Majorana A, Borgna M, et al. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain 2005 115 : 332 7.
38. Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007 14 : 864 71.
39. Ogata J, Minami K, Horishita T, et al. Gargling with sodium azulene sulfonate reduces the postoperative sore throat after intubation of the trachea. Anesth Analg 2005 101 : 290 3.
40. Kohler PF, Winter ME. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Arthritis Rheuma 1985 28 : 1128 32.
41. Tominaga M, Caterina MJ, Malmberg AN, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998 21 : 531 43.
42. Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002 99 : 8400 5.
43. Cui M, Honore P, Zhong C, et al. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci 2006 26 : 9385 93.
44. Kido MA, Muroya H, Yamazu T, Terada Y, Tanaka T. Vanilloid receptor expression in the rat tongue and palate. J Dent Res 2003 82 : 393 7.
45. Heckmann SM, Heckmann JG, Hilz MJ, et al. Oral mucosal blood flow in patients with burning mouth syndrome. Pain 2001 90 : 281 6.
46. Rumsfield JA, West DP. Topical capsaicin in dermatologic and peripheral pain disorders. Ann Pharmacother 1991 25 : 381 7.
47. Kost RG, Straus SE. Postherpertic neuralgia: pathogenesis, treatment and prevention. N Eng J Med 1996 335 : 32 42.
48. Jhaveri MD, Elmes SJ, Kendall DA, Chapman V. Inhibition of peripheral vanilloid TRPV1 receptors reduces noxious heat-evoked responses of dorsal horn neurons in naïve, carrageenan-inflamed and neuropathic rats. Eur J Neurosci 2005 22 : 361 70.
49. Gunthorpe MJ, Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des 2008 14 : 32 41.